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To determine prevalence and longitudinal trends in incidence of MS in Møre and Romsdal
County, Western Norway, from 1950 to 2018.
Methods
Retrospective longitudinal population-based observational study. All patients diagnosed, or
living, with MS in Møre and Romsdal were identified as incident or prevalent cases from local,
regional, and national sources. We compiled the data in the Norwegian Multiple Sclerosis
Registry and Biobank and used the aggregated data set to calculate incidence and prevalence
rates using population measures obtained from Statistics Norway.
Results
On January 1, 2018, the estimated prevalence was 335.8 (95% CI, 314.1–358.5) per 100,000
inhabitants, with a female:male ratio of 2.3. From 1950 through 2017, we observed a considerable
(p < 0.001) increase in average annual incidence rates from 2.1 (95% CI, 1.3–3.3) to 14.4 (95%
CI, 11.9–17.3) per 100,000. From 2005 through 2017, the incidence among women increased
from 17.1 (95% CI, 14.0–20.7) to 23.2 (95% CI, 18.7–28.5) per 100,000, whereas the incidence
among men declined from 10.3 (95% CI, 7.9–13.2) to 5.9 (95% CI, 3.4–8.8) per 100,000.
Conclusion
Møre and Romsdal County in Western Norway has the highest prevalence of MS reported in
Norway. The incidence has steadily increased since 1950, and during the latest 15 years, we
observed opposing trends in sex-specific incidence rates.
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Omitting injuries, MS is the most common cause of neurologic
disability in young adults.1 The majority of patients experience
a relapsing-remitting MS (RRMS) course of the disease fol-
lowing their first clinical attack, as opposed to the primary
progressive MS (PPMS) variant, which is characterized by
gradual progression from disease onset. Numerous disease-
modifying therapies (DMTs) have become available during the
last decades, including a recently approved drug for the treat-
ment of PPMS.2 Despite the growing knowledge of immuno-
logic disease mechanisms in MS, and increasing understanding
of the interplay between environmental and genetic risk factors,
the etiology of the disease remains unknown. Thus, longitu-
dinal investigations, in well-defined populations, applying epi-
demiologic methodsmay reveal clues to novel risk factors while
simultaneously providing measures needed for estimation
of disease burden, resource allocation, and health service
planning.3
We aimed to produce a robust estimate of MS prevalence and
to examine the time trends of incidence during 7 decades in
Møre and Romsdal County, Western Norway.
Methods
Study design
We conducted a retrospective longitudinal population-based
observational study, adhering to the 2015 Standards of
Reporting of Neurological Disorders statement.4
Setting
Møre and Romsdal County is located in Western Norway at
62° N latitude and 7° E latitude. The total area is 14,467 km2,
with islands comprising 11.4% of the area. Neurologic health
care services have been provided for at the Department of
Neurology at Molde Hospital since 1960 and a neurologic
outpatient clinic at Ålesund Hospital since in 1970. Ophthal-
mologic services and neurophysiologic investigations are, and
have been, available at both sites. Agarose gel electrophoresis of
CSF has been available since 1972, and isoelectric focusing
became available from 2004. Evoked response investigations
have been available since 1975 and local access to MRI since
1984. Throughout the study period, we have had access to
advanced laboratory services relevant for the differential di-
agnoses of MS, such as antibody testing for neuromyelitis
optica spectrum disorder. Initially, these analyses were per-
formed abroad, but today this service is established at a Nor-
wegian university clinic laboratory. The university clinics also
provide second opinion services in difficult and less well-
defined cases where the MS diagnosis appears questionable.
The population at risk in 1950 of 191,438 had increased to
266,856 (49.1% women) by January 1, 2018. All together,
11.2% of the population in 2018 constituted immigrants born
outside of Norway, primarily natives from Central Europe.
According to Statistics Norway, the 3 prevailing immigrant
nationalities originated from Poland, Lithuania, and Germany.
Non-European immigrants constituted 4.2% of the total pop-
ulation mainly originating from Eritrea, Syria, The Philippines,
Thailand, and Somalia. Statistics Norway has provided pop-
ulation figures and data on migration dynamics each year since
1951.5 The National Registry has provided information on
place of residence for each patient on prevalence day January 1,
2018. The degree of urbanization in Møre and Romsdal
County has steadily increased since 1945. The proportion of
inhabitants living in densely populated areas increased from
approximately 40% in 1960 to 57% in 1980 and ultimately 72%
in 2018.
Between 1950 and 2018, the average net migration rate was
−0.65 (range −7.15 to 8.57), meaning that for every 1,000
people in Møre and Romsdal at the beginning of the year, less
than 1 person emigrated on average by the end of the year. For
the past decade, the net migration rate has been positive,
ranging from 0.42 to 8.57.
Source population
Historical data included in the present study comprise data
from previously published studies examining the same geo-
graphic area from 1950 to 1991.6–8 In addition, we included
data from 2 unpublished master’s theses at the Faculty of
Medicine, Norwegian University of Science and Technology,
Trondheim, presented in 2009 and 2011. The main and pri-
mary source of information on patients with MS diagnosed in
the subsequent years was the medical records and adminis-
trative database at all 4 county hospitals, including the 2
neurology outpatient clinics in the county. We obtained the
individual case records of patients with MS by searching the
databases using the codes for MS in the ninth (340) and 10th
(G35) revisions of the International Statistical Classification
of Diseases and Related Health Problems. As a supplement,
and on an individual basis, hospitals and outpatient clinics in
other counties, and the patients themselves, supplied missing
information otherwise unattainable. We compiled the merged
data in the Norwegian Multiple Sclerosis Registry and Bio-
bank and performed the statistical analyses based on the ag-
gregated data.9 The Norwegian health care system covers all
residents through a compulsory membership in the National
Insurance Scheme. This ensures universal and equal access to
essential care and specialized medical services, including the
choice of a primary care physician (PCP), i.e., a general
Glossary
CIS = clinically isolated syndrome; CRF = case report form; DMT = disease-modifying therapy; GP = general practitioner;
PCP = primary care physician; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; WHO = World Health
Organization.
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practitioner (GP). Patients who experience symptoms with
acute, subacute, or prolonged onset usually seek help from
their PCP, which serves as a gatekeeper for further specialist
referral, including neurologic services. The neurology out-
patient clinics in the county are both located at the public
hospitals in the cities of Molde and Ålesund. When MS is
suspected, the typical patient trajectory starts at the PCP who
refers the patient to a neurologist employed in the specialized
public health care system where the diagnosis is made,
treatment initiated, and outpatient follow-up established.
Throughout the study period, there have been no private
neurologic practices in the geographic area of interest.
Participants
All patients ascertained in this study had their diagnosis of MS
made by a clinical neurologist in Molde or Ålesund between
1950 and 2018. During this time, 5 different diagnostic cri-
teria, and their respective revisions, have been published.10–17
Patients who did notmeet the diagnostic criteria, including those
with clinically isolated syndrome (CIS), and patients where there
was insufficient information to confirm the diagnosis, were not
included. In cases where the diagnosis was not obvious, the first
(J.S.W.) and last author (R.M.) reached a consensus whether
a patient was eligible for inclusion. We applied a restrictive
strategy in equivocal cases to avoid artifactual inflation.
In the principal study from 1966, the criteria of Allison and
Millar were applied, whereas the criteria of McAlpine were
used in the study from 1991.6,7 Based solely on clinical data,
patients were diagnosed as having definite, probable, or pos-
sibleMS. The 1996 study identified 419 (89 possible) patients
with onset of MS between 1950 and 1991.8 At the same time,
cases labeled as probable and possible in the 2 previously
mentioned studies were reassessed and reclassified in accor-
dance with the McAlpine criteria. In the present study, we
reappraised the original case report forms (CRFs) from this
work and compared the historical data with any follow-up
information and history of disease development available in
the patient’s electronic medical record. We contacted local
and national patient archives for those cases where electronic
records did not exist. All records were screened consistently
for clinical and paraclinical data, including any evidence of
DMT use, results from CSF analyses, and MRI studies. The
patients retrieved from the 2 unpublished dissertations were
diagnosed between 1988 and October 2010, through retro-
spective application of the 2005 revision of the McDonald
criteria. This resulted in the identification of 699 and 981
patients, respectively. The remaining patients diagnosed in
the following years were ascertained using the current revision
of the McDonald criteria at that time. In addition to the cases
deemed definite and probable according to the older clinical
criteria, possible cases were also included in the analyses. The
McDonald criteria do not recognize cases of probable MS.
However, the criteria permit usage of possible labeling in
unsettled cases where patients typically meet some but not all
of the required criteria. Renewed clinical evaluation and
repeated MRI constitute the typical diagnostic follow-up,
which is offered routinely to these patients at our clinic.
For each patient, we recorded a minimum set of data, including
mandatory demographics and certain details of the individual
diagnostic evaluation. We defined disease onset as the year
when a patient first experienced a symptom suggestive of MS.
Correspondingly, we defined the time of diagnosis as the year,
when a clinical neurologist made the diagnosis of MS.
We categorized patients as having either relapsing-onset MS
(RRMS) or progressive-onset MS (PPMS) based on their
medical history and findings on the clinical neurologic exami-
nation at the time of diagnosis. We did not record data on
familial cases or determine the proportion of patients developing
secondary progressive MS following an initial RRMS course.
Every entry to the Norwegian Multiple Sclerosis Registry is
based on the unique 11-digit national identification number
issued to each citizen at birth or whenmoving to Norway. The
first 6 digits of this number equal a person’s date of birth
(DD/MM/YY). Thus, we avoid duplicate entries when using
multiple data sources and any missing data when calculating
a patient’s age at disease onset and diagnosis.
Measurement
Patients living inMøre and Romsdal County on prevalence day
January 1, 2018 were defined as prevalent cases. Deceased
patients and nonresidents were excluded from the prevalence
cohort. We also excluded patients who did not meet the di-
agnostic criteria or had other medical conditions that better
could explain their symptoms. The clinical and demographic
data for the 896 prevalent cases are presented in table 1. The
crude prevalence rate was calculated as the total number of
patients per 100,000 inhabitants using ascertained cases from
1950 to 2018 as the numerator and the 2018 census on January
1, 266,856, as the denominator.
Cases were considered incident if the diagnosis of MS was
made by a clinical neurologist in either Molde or Ålesund
between 1950 and 2018. Average annual incidence rates were
estimated retrospectively for quinquennial intervals, using the
average population in each 5-year period as the denominator.
The time delay between onset and diagnosis was also calcu-
lated (in years) for the same time intervals. The clinical and
demographic data for the 1,184 patients constituting the in-
cidence cohort are presented in table 2.
Statistical methods
We calculated the age-adjusted prevalence and incidence
rates, using data from both the European standard population
of 2013 and the World Health Organization (WHO) world
standard population.18,19 The Mann-Whitney test was used
for comparing differences in age at onset, age at diagnosis, and
diagnostic delay between women, men, RRMS, and PPMS.
For all the calculations regarding prevalence and incidence,
we assumed an underlying Poisson distribution of the disease.
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A test for trend in ordered Poisson rates was used to assess the
observed change in incidence over time.
Single-year population data, in age groups, have only been
available since 1970. However, county censuses undertaken in
1950 and 1960 contained this information. We used linear
interpolation based on these 2 censuses to supply the missing
population data from 1950 to 1960 and from 1960 to 1970.
Standard protocol approvals, registrations,
and patient consents
This study was approved by the Central Regional Committee
for Medical and Health Research Ethics, #2015/2024/REK
midt.
Data availability
The Norwegian Multiple Sclerosis Registry and Biobank holds
ownership of the patient data used in this study. However, any
anonymized data can be made available for research purposes
on reasonable request to the corresponding author.
Results
Main findings
Altogether, we identified 1,422 patients (figure 1), of whom
896 were recognized as prevalent on January 1, 2018, resulting
in a crude prevalence of 335.8 (95% CI, 314.1–358.5) per
100,000. Adjusted prevalence was equal to 350.4 per 100,000
for the European standard population and 356.6 per 100,000
for the WHO standard population. For women, we found
a prevalence rate of 472.8 (95% CI, 436.4–511.6) per 100,000
and for men 203.8 (95% CI, 180.5–229.2) per 100,000
resulting in a female:male ratio of 2.3. For the age-specific
prevalence, rates peaked among women aged 40–49 years and
men aged 30–39 years (figure 2A).
There was almost a sevenfold (p < 0.001) increase in the
crude incidence rate from 2.1 (95% CI, 1.3–3.2) per 100,000
during 1950–1954 to 14.4 (95% CI, 11.9–17.3) during
2015–2017 (table 3). For these 2 time periods, the female:
male incidence ratio changed from 1.33 to 3.93.
Discussion
We have shown a steady increase in the incidence and prev-
alence of MS in Møre and Romsdal County during almost 7
decades. We report one of the highest prevalence rates, 335.8
per 100,000, recorded to date in Europe.20–22 From 1961 to
2018, there has been more than a 13-fold increase in the
prevalence of MS in Møre and Romsdal County.
During the first 3 decades of the study period, the crude
incidence of MS remained rather stable, and it did not exceed
10 new cases per 100,000 before the millennial shift. A steady
increase could be seen from 2000 and toward the end of the
study period. The increment in MS incidence in Møre and
Table 1 Clinical and demographic data for theMS cohort inMøre and Romsdal County on prevalence day January 1, 2018
































37 (46) 43 (38) 5 (23) 59
(9.9)
47 (50) 55 (46) 5 (31.3) 88
(9.8)
44 (57) 50.5 (50) 5 (31)
RRMS 274
(90.4)
30 (47) 34.5 (46) 2 (36) 534
(90.1)
35 (60) 40 (62) 2 (52) 808
(90.2)
33 (52) 38 (62) 2 (52)




30 (43) 34.5 (46) 2 (36) 411
(69.3)
35 (55) 41 (62) 2 (41) 619
(69.1)
33 (55) 39 (62) 2 (49)
Male 95
(31.4)
32 (48) 37 (46) 2 (24) 182
(30.7)
38 (56) 41 (52) 1.5 (52) 277
(30.9)
36 (59) 39 (55) 2 (52)
p Value 0.076 0.15 0.29 0.033 0.36 0.013 0.012 0.15 0.17
Total 303
(100)
31 (48) 35 (46) 2 (36) 593
(100)
36 (62) 41 (62) 2 (52) 896
(100)
34 (65) 39 (62) 2 (52)
Abbreviations: PPMS = primary progressive MS; RRMS = relapsing-remitting MS.
a Median age, in years, at first symptom suggestive of MS.
b Median age, in years, at the time of diagnosis.
c Median diagnostic delay, in years, from first symptom onset to diagnosis.
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Table 2 Clinical and demographic data for the incidence cohort 1950–2018



























39 (51) 47 (67) 3.5 (53.5) 62
(10.6)
46 (50) 53 (43) 3.5 (30.9) 139
(11.7)
42(57) 51 (67) 3.5 (53.5)
RRMS 522
(87.1)
31 (54) 37 (57) 2.5 (44.5) 523
(89.4)
35 (55) 41 (58) 1.5 (62.5) 1,045
(88.3)
33 (55) 39 (60) 1.5 (62.5)




31 (52) 38 (63) 2.5 (44.5) 403
(68.9)
35 (63) 41 (58) 1.5 (62.5) 780 (65.9) 33 (55) 40 (63) 1.9 (62.5)
Male 222
(37.1)
32 (53) 39 (71) 2.5 (53.5) 182
(31.1)
37 (56) 41 (52) 1.5 (51.5) 404 (34.1) 35 (59) 40.5 (71) 2 (53.5)
p Value 0.037 0.103 0.58 0.069 0.32 0.035 0.005 0.053 0.59
Total 599
(100)
32 (55) 39 (71) 2.5 (53.5) 585
(100)
36 (62) 41 (58) 1.5 (62.5) 1,184
(100)
34 (62) 40 (71) 1.9 (62.5)
Abbreviations: PPMS = primary progressive MS; RRMS = relapsing-remitting MS.
a Median age, in years, at first symptom suggestive of MS.
b Median age, in years, at the time of diagnosis.































Romsdal from 2005 and onward is mainly caused by the
increase in incidence among women. The corresponding rates
for men have declined during the same period (figure 2B).
Our study is limited by the retrospective design and the
application of various diagnostic criteria throughout the
study period, which makes direct comparison of incidence
rates throughout the study less feasible. There have been
repeated surveys on MS in Møre and Romsdal County, and
this would presumably raise the attention among GPs and in
the general population as well. This could lead to a higher
ascertainment probability. With the introduction of DMTs
in the county during 1996, MS became a treatable disease.
This fact probably contributed to patients, having milder
symptom burdens and less disabling disease courses, being
brought to attention earlier than previously due to raised
expectations for swifter diagnostic resolution among GPs
and the public. The fact that diagnostic delay has remained
consistent and short from 1995 toward the end of 2017
would also allude to this (table 3).
Cases were recognized as incident at the time of diagnosis, and
not at disease onset, as reliable information regarding place of
residence at disease onset was unavailable. Thus, it remains
plausible that a patient diagnosed in Møre and Romsdal and
consequently recognized as incident might have had disease
onset outside the county. Conversely, we are unable to account
for patients with disease onset in Møre and Romsdal where the
diagnosis was made elsewhere. However, and due to the min-
imal migration flux, this would probably only pertain to a neg-
ligible amount of cases. Patients’ recollections concerning time
of disease onset are subject to recall bias. This could affect our
estimation of diagnostic delay, as this variable equals the time
gap between the time point a patient remembering having their
first symptoms suggestive ofMS, and the diagnosis being made.
Unlike many other studies, cases labeled as possible according
to the older diagnostic criteria based on clinical data only were
included in our analyses. This would affect ascertainment
probability and could lead to overestimation if patients ini-
tially labeled as possible ultimately did not develop MS.
However, all the original CRFs detailing cases originally
ascertained by outdated diagnostic criteria have been
reviewed and linked with each patient’s medical history and
results from relevant ancillary investigations. Furthermore,
and due to our study’s longitudinal design and the stability of
the population during the study period, we assume that
possible cases with protracted disease courses, for instance,
a patient with CIS without any evidence of a second clinical
attack for many years, are largely, if not completely accounted
for. Previously published work from Møre and Romsdal
County showed a notable (p < 0.0001) increase in incidence
rates from 1950 to 1991.9 The significance of this increase did,
however, not diminish whether possible cases were included.
Furthermore, the same authors showed that inclusion of
possible cases in the prevalence analyses resulted in an in-
crease of 33.2% and 32.5% for the 1965 and 1985 data, re-
spectively. Thus, the effect size of including cases of equivocal
certainty appears to be comparable and consistent over time.
A previously published nationwide study of MS prevalence in
Norway pooled data from several registries, including the
Norwegian Multiple Sclerosis Registry, and showed that the
central health region, which includes Møre and Romsdal
County, to have the highest crude prevalence, 249 (95% CI,
238–261) per 100,000.23 This was also confirmed by a report
including data from the Norwegian Patient Registry.24 We
suspect that the discrepancy in prevalence rates, when com-
paring our results with these registry-based studies, is caused
by methodological differences. First, the method of case as-
certainment, not being based on critical reappraisal of clinical
and paraclinical individual patient data, is notably different.
Second, before the present study and at the time when these
studies were conducted, the coverage of the Norwegian
Multiple Sclerosis Registry, one of their main data sources,
was incomplete. Third, acknowledging that the pooled results
Figure 1 Flow diagram illustrating inclusion and exclusion to the prevalence and incidence cohorts
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are presented regionally, any local differences in prevalence
across counties will not be depicted. Our last claim is sup-
ported by a previous report from another county (Nord-
Trøndelag) located within the same region as Møre and
Romsdal where the authors, using a similar study design, but
different diagnostic criteria, demonstrated a considerably
lower crude prevalence rate of 163.6 (95% CI, 142.2–187.5)
per 100,000 in 2000.25
Other Norwegian single-county studies (Buskerud, Hordaland,
and Nordland) conducted more recently, have also demon-
strated lower prevalence rates compared with our results.26–28
The median diagnostic delay reported in Nord-Trøndelag and
Hordaland is comparable to our results, whereas the diagnostic
delay in Buskerud andNordland appears to be somewhat longer.
Comparable prevalence rates as those demonstrated in the
present study were recently shown among adults in the
Midwestern and Northeastern parts of the United States in
a study exploiting administrative health claims data.
Depending on the applied methods of adjustment,
nationwide prevalence rates of 265.1 and 309.2 per 100,000
could be demonstrated during 2010.29 Another recent study
reports an island-wide prevalence of 330 (95% CI, 321–338)
per 100,000 on March 31, 2016, in Sardinia, Italy, with re-
gional prevalence rates more than twice as high as those
previously reported from mainland Italy.22 However, the
authors of this study emphasize the role of genetic factors
contributing to a higher burden of immune-mediated diseases
among Sardinians, corroborating previous studies.30
The Hordaland study from 2016 demonstrated stable in-
cidence rates over the past 30 years, whereas our data show
an increase in crude incidence within the same timeframe.27
In our study, the largest increase in average annual incidence
rates between 2 consecutive time periods is seen between
1995–1999 and 2000–2004, from 7.5 to 12.5. We assume
that the introduction of the original McDonald criteria of
2001 is the principal factor responsible for this rise. This
observation further emphasizes an important point when
conducting epidemiologic studies where the diagnostic cri-
teria are changing throughout the study period. That is, the
Figure 2 Age-specific prevalence and incidence of MS in Møre and Romsdal County
Age-specific prevalence on January 1, 2018 (A), and
trends in crude and sex-specific average annual in-
cidence during 1950–2018 in 5-year periods (B).
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increased diagnostic accuracy of newer criteria. For MS,
these criteria have become gradually more dependent on
sensitive CSF analyses and advanced MRI, which un-
doubtedly has contributed to increased diagnostic precision,
and probably earlier detection of definite cases. However,
the longitudinal design of our study and the scrutinization of
individual patient records provided us with extensive follow-
up information, particularly valuable for indolent cases and
in participants originally ascertained by application of the
older diagnostic criteria.
Most recently, and for the past 15 years, the increase in crude
incidence is a direct result of an increase in incidence among
women. As pointed out by other authors, sex ratio typically
exhibits a propensity to increase over time when the same
geographic area is investigated repeatedly.31 They provide 3
examples of counties, which serve as an exception to this rule;
Møre and Romsdal and Nord-Trøndelag in Norway and
Olmsted in Minnesota, United States. However, in the present
updated study, an asymmetric distribution between sexes is
clearly evident, both for the prevalence numbers and the most
recent incidence data. Given stability in the population gene
pool, the same authors argue that short-term changes in the
incidence of MS are suggestive of etiologic environmental risk
factors. The marked increase in incident female:male sex ratio in
the 3 latest time periods of our study, from 1.66 during
2005–2009 to 3.93 during 2015–2017, lends support to this
notion as we have no reason to assume inequality in the acces-
sibility of health care services in this period. The overall differ-
ence in diagnostic delay betweenmen andwomenwasminor for
both the prevalence (p = 0.17) and incidence (p = 0.59) cohort.
Without complementary data, we are only able to speculate on
any contributing environmental risk factors, such as smoking
habits, hypovitaminosis D, or obesity, that might be relevant for
these observations.
In this study, we show a high point prevalence and increasing
incidence of MS in Møre and Romsdal County in Western
Norway through almost 7 decades. Improved diagnostic tools,
temporal changes in diagnostic criteria, increased public aware-
ness, access toDMTs, and increased survival among patients due
to improved symptomatic treatment and prevention of com-
plications are likely contributing factors that in part could explain
the observed incline in MS incidence and prevalence, but
changes in environmental risk factors during almost 70 years
might also play a role. Further studies should seek to elucidate
the underlying mechanisms responsible for the observed
changes.
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1950–1954 197,008 7.5 12 2.4 1.2–4.2 9 1.8 0.8–3.5 21 2.1 1.3–3.3 2.2; 2.2
1955–1959 208,561 7.5 11 2.1 1.1–3.8 10 1.9 0.9–3.5 21 2.0 1.2–3.1 2.2; 2.1
1960–1964 214,902 9.5 27 5.0 3.3–7.3 18 3.3 2.0–5.3 45 4.2 3.1–5.6 4.7; 4.4
1965–1969 220,658 1.5 17 3.1 1.8–5.0 9 1.6 0.7–3.1 26 2.4 1.6–3.4 2.6; 2.7
1970–1974 227,523 3.5 31 5.5 3.7–7.8 17 3.0 1.7–4.8 48 4.2 3.1–5.6 5.2; 5.1
1975–1979 233,898 2.5 31 5.3 3.6–7.6 16 2.7 1.6–4.4 47 4.0 3.0–5.3 4.6; 4.6
1980–1984 236,062 1.7 39 6.6 4.7–9.1 37 6.3 4.4–8.6 76 6.4 5.1–8.1 7.2; 7.1
1985–1989 237,766 2.0 55 9.2 7.0–12.0 28 4.7 3.1–6.8 83 7.0 5.6–8.6 7.6; 7.5
1990–1994 239,221 2.5 69 11.5 9.0–14.6 44 7.4 5.3–9.9 113 9.4 7.8–11.4 9.7; 9.8
1995–1999 242,046 1.5 65 10.8 8.3–13.7 26 4.3 2.8–6.3 91 7.5 6.1–9.2 7.8; 7.7
2000–2004 244,247 1.5 105 17.2 14.1–20.9 48 7.8 5.8–10.4 153 12.5 10.6–14.7 12.9; 12.3
2005–2009 247,425 1.5 105 17.1 14.0–20.7 64 10.3 7.9–13.2 169 13.7 11.7–15.9 14.3; 14.3
2010–2014 259,037 1.5 122 19.1 15.9–22.8 54 8.2 6.2–10.7 176 13.6 11.7–15.8 14.2; 14.0
2015–2017 266,140 1.5 91 23.2 18.7–28.5 24 5.9 3.4–8.8 115 14.4 11.9–17.3 14.8; 14.3
Abbreviation: WHO = World Health Organization.
a Diagnostic delay, in years, from first symptom onset to diagnosis.
b Adjusted to the European standard population.
c Adjusted to the WHO standard population.
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